PPAR Gamma in Neuroblastoma: The Translational Perspectives of Hypoglycemic Drugs
Neuroblastoma (NB) is the most common and aggressive pediatric cancer, characterized by a remarkable phenotypic diversity and high malignancy. The heterogeneous clinical behavior, ranging from spontaneous remission to fatal metastatic disease, is attributable to NB biology and genetics. Despite majo...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2016-01-01
|
| Series: | PPAR Research |
| Online Access: | http://dx.doi.org/10.1155/2016/3038164 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832550077666689024 |
|---|---|
| author | Serena Vella Pier Giulio Conaldi Tullio Florio Aldo Pagano |
| author_facet | Serena Vella Pier Giulio Conaldi Tullio Florio Aldo Pagano |
| author_sort | Serena Vella |
| collection | DOAJ |
| description | Neuroblastoma (NB) is the most common and aggressive pediatric cancer, characterized by a remarkable phenotypic diversity and high malignancy. The heterogeneous clinical behavior, ranging from spontaneous remission to fatal metastatic disease, is attributable to NB biology and genetics. Despite major advances in therapies, NB is still associated with a high morbidity and mortality. Thus, novel diagnostic, prognostic, and therapeutic approaches are required, mainly to improve treatment outcomes of high-risk NB patients. Among neuroepithelial cancers, NB is the most studied tumor as far as PPAR ligands are concerned. PPAR ligands are endowed with antitumoral effects, mainly acting on cancer stem cells, and constitute a possible add-on therapy to antiblastic drugs, in particular for NB with unfavourable prognosis. While discussing clinical background, this review will provide a synopsis of the major studies about PPAR expression in NB, focusing on the potential beneficial effects of hypoglycemic drugs, thiazolidinediones and metformin, to reduce the occurrence of relapses as well as tumor regrowth in NB patients. |
| format | Article |
| id | doaj-art-7085628a57b1425494c73a48ec0f65d3 |
| institution | Kabale University |
| issn | 1687-4757 1687-4765 |
| language | English |
| publishDate | 2016-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | PPAR Research |
| spelling | doaj-art-7085628a57b1425494c73a48ec0f65d32025-02-03T06:07:48ZengWileyPPAR Research1687-47571687-47652016-01-01201610.1155/2016/30381643038164PPAR Gamma in Neuroblastoma: The Translational Perspectives of Hypoglycemic DrugsSerena Vella0Pier Giulio Conaldi1Tullio Florio2Aldo Pagano3Department of Laboratory Medicine and Advanced Biotechnologies, IRCCS-ISMETT (Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione), Palermo, ItalyDepartment of Laboratory Medicine and Advanced Biotechnologies, IRCCS-ISMETT (Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione), Palermo, ItalySection of Pharmacology, Department of Internal Medicine (DiMI) and Center of Excellence for Biomedical Research (CEBR), University of Genova, Genova, ItalyDepartment of Experimental Medicine (DIMES), University of Genova, Genova, ItalyNeuroblastoma (NB) is the most common and aggressive pediatric cancer, characterized by a remarkable phenotypic diversity and high malignancy. The heterogeneous clinical behavior, ranging from spontaneous remission to fatal metastatic disease, is attributable to NB biology and genetics. Despite major advances in therapies, NB is still associated with a high morbidity and mortality. Thus, novel diagnostic, prognostic, and therapeutic approaches are required, mainly to improve treatment outcomes of high-risk NB patients. Among neuroepithelial cancers, NB is the most studied tumor as far as PPAR ligands are concerned. PPAR ligands are endowed with antitumoral effects, mainly acting on cancer stem cells, and constitute a possible add-on therapy to antiblastic drugs, in particular for NB with unfavourable prognosis. While discussing clinical background, this review will provide a synopsis of the major studies about PPAR expression in NB, focusing on the potential beneficial effects of hypoglycemic drugs, thiazolidinediones and metformin, to reduce the occurrence of relapses as well as tumor regrowth in NB patients.http://dx.doi.org/10.1155/2016/3038164 |
| spellingShingle | Serena Vella Pier Giulio Conaldi Tullio Florio Aldo Pagano PPAR Gamma in Neuroblastoma: The Translational Perspectives of Hypoglycemic Drugs PPAR Research |
| title | PPAR Gamma in Neuroblastoma: The Translational Perspectives of Hypoglycemic Drugs |
| title_full | PPAR Gamma in Neuroblastoma: The Translational Perspectives of Hypoglycemic Drugs |
| title_fullStr | PPAR Gamma in Neuroblastoma: The Translational Perspectives of Hypoglycemic Drugs |
| title_full_unstemmed | PPAR Gamma in Neuroblastoma: The Translational Perspectives of Hypoglycemic Drugs |
| title_short | PPAR Gamma in Neuroblastoma: The Translational Perspectives of Hypoglycemic Drugs |
| title_sort | ppar gamma in neuroblastoma the translational perspectives of hypoglycemic drugs |
| url | http://dx.doi.org/10.1155/2016/3038164 |
| work_keys_str_mv | AT serenavella ppargammainneuroblastomathetranslationalperspectivesofhypoglycemicdrugs AT piergiulioconaldi ppargammainneuroblastomathetranslationalperspectivesofhypoglycemicdrugs AT tullioflorio ppargammainneuroblastomathetranslationalperspectivesofhypoglycemicdrugs AT aldopagano ppargammainneuroblastomathetranslationalperspectivesofhypoglycemicdrugs |